Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment

Journal of Rheumatology

Volumn 28, Issue 3, 2001, Pages 496-501

  Seitz, M ^a   Zwicker, M ^a   Wider, B ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Interleukin 10; Methotrexate; Peripheral blood mononuclear cells; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 10; LIPOPOLYSACCHARIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOHEMAGGLUTININ; PREDNISONE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DETERIORATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STIMULATION; SUPERNATANT; TARGET CELL; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; FEMALE; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; METHOTREXATE; MIDDLE AGED; PHYTOHEMAGGLUTININS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035091423     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Efficacy of low dose methotrexate in rheumatoid arthritis
2. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
3. Long-term prospective study of the use of methotrexate in rheumatoid arthritis: Update after a mean of 90 months
4. The mechanisms of action of methotrexate in rheumatoid arthritis: The search continues
5. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells
6. The antiinflammatory mechanism of methotrexate: Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation
7. The effects of methotrexate and hydroxyurea on neutrophil chemotaxis
8. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low dose methotrexate
9. Methotrexate action in rheumatoid arthritis: Stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells
10. Interleukin I (IL-1) receptor antagonist, soluble tumor necrosis factor receptors. IL-1β and IL-8 - Markers of remission in rheumatoid arthritis during treatment with methotrexate
11. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes
12. Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment
13. Antiinflammatory and immuno-regulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased IL-4 and IL-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction
14. rHUIL-10 in subjects with active rheumatoid arthritis: A phase 1 and cytokine response study
15. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts
16. Endogenous interleukin-10 in inflammatory disorders: Regulatory roles and pharmacological modulation
17. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis
18. Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats
19. Interleukin-10 inhibition of the progression of established collagen-induced arthritis
20. Recombinant human IL-10 prevents the onset of diabetes in the non-obese diabetic mouse
21. Interleukin-10 prevents experimental allergic encephalo-myelitis in rats
22. Curative and protective effects of IL-10 in experimental autoimmune thyroiditis (EAT). Evidence for IL-10 enhanced cell death in EAT
23. Differential effects of interleukin-10 and -4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis
24. Balance of IL-1 receptor antagonist/1L-Ibeta in rheumatoid synovium and its regulation by IL-4 and IL-10
25. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis
26. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium
27. Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis
28. Immunoregulatory role of interleukin-10 in rheumatoid arthritis
29. Prevention and reversal of cartilage degradation in rheumatoid arthritis by IL-10 and IL-4
30. Elevated interleukin-10 levels in patients with rheumatoid arthritis
31. Interleukin-10 in rheumatoid arthritis
32. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis
33. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
34. Isolation of lymphocytes, granulocytes and macrophages
35. Nonspecific esterase stain for the identification of monocytes and macrophages
36. Circulating interleukin-10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: Preliminary report
37. Adenosine enhances IL-10 secretion by human monocytes
38. The mechanism of action of methotrexate
39. Molecular and cellular effects of methotrexate
40. A randomized, controlled trial of IL-10 in humans
41. Mononuclear phagocytes and rheumatoid synovitis: Mastermind or workhorse in arthritis?
42. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4